Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9303)	3/20/1999 10:21:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Sounds good to me. Back to waiting for end of trial.

To: aknahow who wrote (9303)	3/20/1999 10:44:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

I sure wish you all would either decide whether or not to believe protocol announced in various places for all to see. I sure don't see anything about homogenicity, messiness, arms, legs or stratification. They even provide phone number if one is so inclined. Texas big D thanks for the info provided in that GREAT LONE STAR STATE publication! Project Title: Phase III Randomized, Placebo Controlled Multicenter Trial to Assess the Safety and Efficacy of rBPI21, in the Adjunctive Treatment of Pediatric Patients with Severe Meningococcal Disease Principal Investigator: John Bradley, M.D. IRB Reference Number: #0655 Description: A randomized study for children with menningococcemia. Children receive placebo or rBPI21, in addition to their normal treatment Eligibility Criteria: Gender: Both Age: Three months old to eighteen years old Disease Name: Menningococcemia Other Criteria: Patients must have presumptive diagnosis of meningococcemia; Glascow menningococcal Septicemia Prognostic Score >8; must receive BPI21 within eight hours of the first dose of antibiotic Exclusion Criteria: None listed Location: Children's Hospital-San Diego, 3020 Children's Way, San Diego, CA 92123 Requires Inpatient Stay: Yes Facility where the study is being done: Children's Hospital-San Diego, 3020 Children's Way, San Diego, CA 92123 Compensation: None Contact Name: Infectious Disease Research Office Contact Phone: (619) 495-7785